Filing Details
- Accession Number:
- 0001415889-24-029376
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-13 19:52:26
- Reporting Period:
- 2024-12-11
- Accepted Time:
- 2024-12-13 19:52:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1671858 | Ars Pharmaceuticals Inc. | SPRY | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1380762 | Brian Dorsey | C/O Ars Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego CA 92130 | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-12-11 | 15,000 | $0.64 | 21,024 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-11 | 15,000 | $12.43 | 6,024 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-12-12 | 25,000 | $0.64 | 31,024 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-12-12 | 25,000 | $12.30 | 6,024 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-11 | 15,000 | $0.00 | 15,000 | $0.64 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-12 | 25,000 | $0.00 | 25,000 | $0.64 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
46,828 | 2028-11-28 | No | 4 | M | Direct | |
21,828 | 2028-11-28 | No | 4 | M | Direct |
Footnotes
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023.
- The weighted average sale price for the transaction report was $12.4284, and the range of prices were between $12.34 and $12.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction report was $12.2973, and the range of prices were between $12.13 and $12.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- Immediately exercisable.